MYCN and neuroblastoma: Amplification of the MYCN oncogene is present in ~25% of all neuroblastomas and is a marker for aggressive tumors, and in line with a differentiated phenotype, we detected lower N‐Myc expression in our PDX cells following IBL‐302 treatment.